九典制药(300705) - 九典制药投资者关系管理信息

Group 1: Company Performance and Strategy - The company is currently progressing according to its annual operational plan, with a positive business trend expected in the upcoming semi-annual report [2] - The impact of recent national medical insurance price comparison policies on the company has not yet been significant, but the company remains vigilant regarding policy changes [2][3] - The company will continuously monitor policy dynamics and adjust its strategic direction to maintain stable development in a changing market environment [3] Group 2: Product Pricing and Market Position - The price reduction of the drug Loxoprofen Sodium Gel Patch is anticipated due to the nationwide implementation of centralized procurement policies [3] - As of now, the Loxoprofen Sodium Gel Patch has been executed in 19 regions under centralized procurement, achieving a positive cycle of price-for-volume exchange [3] - The sales model for Loxoprofen Sodium Gel Patch differs from that of Ketoprofen Gel Patch, with the former trialing a semi-self-operated model in three provinces [3] Group 3: Employee Incentives and Governance - The company plans to establish a regular equity incentive system to enhance employee motivation and cohesion, promoting a sense of responsibility and mission for sustainable development [4]